Charles J Montgomery

Address:

1438 Carleton Dr, Concord, CA 94518

Phone:

9257656117

VIN:

3TMLU4EN1BM064030

Make:

TOYOTA

Model:

TACOMA

Year:

2011

US Patent:

7287761, Oct 30, 2007

Filed:

Dec 9, 2004

Appl. No.:

11/007854

Inventors:

Charles James Montgomery - Concord CA, US

International Classification:

B60G 17/052

US Classification:

280 5514, 280 6157, 280 55

Abstract:

A motorized assembly having a handlebar control switch assembly which allows the height and load carrying capacity of the motorized assembly to be quickly and easily modified without requiring a user to remove their hands from the handlebar portion of the motorized assembly.

US Patent:

7931902, Apr 26, 2011

Filed:

Jul 18, 2006

Appl. No.:

11/814549

Inventors:

Frederic J. de Sauvage - Foster City CA, US
Gretchen Frantz - San Francisco CA, US
Charles Montgomery - Jay OK, US
Franklin Peale - San Carlos CA, US
Mary Jean Sparks - Magnolia TX, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A01K 67/00
A61K 39/395
A61P 43/00

US Classification:

4241721, 800 3, 800 13, 800 9

Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO226, PRO257, PRO268, PRO290, PRO36006, PRO363, PRO365, PRO382, PRO444, PRO705, PRO1071, PRO1125, PRO1134, PRO1155, PRO1281, PRO1343, PRO1379, PRO1380, PRO1387, PRO1419, PRO1433, PRO1474, PRO1550, PRO1571, PRO1572, PRO1759, PRO1904, PRO35193, PRO4341, PRO4348, PRO4369, PRO4381, PRO4407, PRO4425, PRO4985, PRO4989, PRO5737, PRO5800, PRO5993, PRO6017, PRO7174, PRO9744, PRO9821, PRO9852, PRO9873, PRO10196, PRO34778, PRO20233, PRO21956, PRO57290, PRO38465, PRO38683 or PRO85161 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

US Patent:

20090196876, Aug 6, 2009

Filed:

Oct 18, 2005

Appl. No.:

11/577547

Inventors:

Fred de Sauvage - Foster City CA, US
Dorothy French - San Carlos CA, US
Lino Gonzalez - Menlo Park CA, US
Asja Praetor - Singapore, SG
Weilan Ye - Foster City CA, US
Katherin E. Combs - Spring TX, US
Zhiyong Ding - Longmont CO, US
Allison Anne Byers Horner - Dickinson TX, US
Erin Marie Massey - Conroe TX, US
Charles Montgomery - Jay OK, US
Laurie Jeanette Minze - Katy TX, US
Carolina Rangel - Houston TX, US
Tracy Ellen Willis Sevaux - Conroe TX, US
Mary Jean Sparks - Magnolia TX, US
Joy Anne Stala - The Woodlands TX, US
Peter Vogel - The Woodlands TX, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 39/395
G01N 33/00
C12N 5/10
C07K 16/18
A61P 27/00
A61P 25/00
A61P 25/18
A61P 25/22
A61P 37/00
A61P 13/12
A61P 3/00
A61P 19/00
A61P 9/00
A61P 35/00
A61P 41/00
A61P 3/10

US Classification:

4241581, 800 3, 435325, 435352, 5303871

Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO194, PRO220, PRO241, PRO284, PRO331, PRO354, PRO355, PRO533, PRO541, PRO725, PRO937, PRO1014, PRO1120, PRO1182, PRO1325, PRO1382, PRO1410, PRO1555, PRO1556, PRO1760, PRO1787, PRO1868, PRO4326, PRO4332, PRO4346, PRO4400, PRO6003, PRO6094, PRO6244, PRO9820, PRO9828, PRO10274, PRO16090, PRO19644, PRO21340, PRO92165, PRO85143, PRO1124, PRO1026 or PRO23370 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

US Patent:

20120210450, Aug 16, 2012

Filed:

Apr 8, 2011

Appl. No.:

13/082706

Inventors:

Fred de Sauvage - Foster City CA, US
Dorothy French - San Carlos CA, US
Lino Gonzalez - Menlo Park CA, US
Asja Praetor - Singapore, SG
Weilan Ye - Foster City CA, US
Katherin E. Combs - Spring TX, US
Zhiyong Ding - Longmont CO, US
Allison Anne Byers Horner - Dickinson TX, US
Erin Marie Massey - Conroe TX, US
Charles Montgomery - Jay OK, US
Laurie Jeanette Minze - Katy TX, US
Carolina Rangel - Houston TX, US
Tracy Ellen Willis Sevaux - Conroe TX, US
Mary Jean Sparks - Magnolia TX, US
Joy Anne Stala - The Woodlands TX, US
Peter Vogel - The Woodlands TX, US

International Classification:

G01N 33/48

US Classification:

800 3

Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO194, PRO220, PRO241, PRO284, PRO331, PRO354, PRO355, PRO533, PRO541, PRO725, PRO937, PRO1014, PRO1120, PRO1182, PRO1325, PRO1382, PRO1410, PRO1555, PRO1556, PRO1760, PRO1787, PRO1868, PRO4326, PRO4332, PRO4346, PRO4400, PRO6003, PRO6094, PRO6244, PRO9820, PRO9828, PRO10274, PRO16090, PRO19644, PRO21340, PRO92165, PRO85143, PRO1124, PRO1026 or PRO23370 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.